Compare AWX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWX | SNTI |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.1M |
| IPO Year | 1998 | 2021 |
| Metric | AWX | SNTI |
|---|---|---|
| Price | $2.71 | $0.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 23.2K | ★ 227.3K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,090,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $2.40 | $0.33 |
| 52 Week High | $5.43 | $2.88 |
| Indicator | AWX | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 35.46 |
| Support Level | $2.50 | $0.33 |
| Resistance Level | $2.91 | $0.40 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 59.17 | 24.07 |
Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment, which is the key revenue driver, provides hazardous and non-hazardous brokerage and management services to industrial, commercial, municipal, and governmental customers, captive landfill management for an industrial customer, and saltwater injection well operations. Its Golf and related operations segment consists of four golf courses and associated clubhouses, which provide dining and banquet facilities, a hotel which provides lodging and resort-related amenities.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).